XOMA Royalty Shares Are Trading Higher After the Company Announced Its Economic Interest in Seralutinib, a Phase 3 Asset Studying Pulmonary Arterial Hypertension.
XOMA Royalty Shares Are Trading Higher After the Company Announced Its Economic Interest in Seralutinib, a Phase 3 Asset Studying Pulmonary Arterial Hypertension.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated